SCHEDULE 13G/A: Armistice Capital and Steven Boyd Maintain 4.99% Stake in Eledon Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have reported a 4.99% beneficial ownership stake in Eledon Pharmaceuticals, Inc. as of December 31, 2024, through a Schedule 13G/A filing.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 3,137,553 shares of Eledon Pharmaceuticals, Inc. common stock.
• This ownership represents 4.99% of the company's outstanding common stock, based on information from the Issuer.
• The shares are held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and an investment advisory client of Armistice Capital.
• Armistice Capital, LLC, as the investment manager, exercises shared voting and dispositive power over these securities.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is also deemed to beneficially own these shares.
• The filing is an Amendment No. 2 to Schedule 13G, indicating an update to a previously reported ownership position.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Eledon Pharmaceuticals, Inc.

Sentiment

Score: 6

Explanation: The filing indicates a significant, passive institutional stake, suggesting continued confidence in the issuer without intent to influence control, which is generally a neutral to slightly positive signal.

Positives

• The continued holding of a significant stake (4.99%) by Armistice Capital and Steven Boyd indicates ongoing institutional investor interest and confidence in Eledon Pharmaceuticals, Inc.

Future Outlook

This Schedule 13G/A filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Eledon Pharmaceuticals, Inc. or the reporting persons regarding the company's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects routine institutional investor activity within the pharmaceutical sector, where investment firms like Armistice Capital acquire passive stakes in publicly traded companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming a notable investor's continued passive stake in the company.

Key Dates

Keywords

Eledon Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment, pharmaceuticals